MICAL-L2 Is Essential for c-Myc Deubiquitination and Stability in Non-small Cell Lung Cancer Cells
Open Access
- 14 January 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
Abstract
Objectives: MICAL-L2, a member of the molecules interacting with the CasL (MICAL) family, was reported to be highly expressed in several types of cancers, however, the roles of MICAL-L2 in NSCLC pathogenesis remain to be explored. This study is designed to clarify the mechanisms by which MICAL-L2 participates in NSCLC cell proliferation. Materials and Methods: The expression levels of MICAL-L2 in human lung cancer samples were assessed by immunohistochemical staining. Cells were transfected with siRNA or plasmids to regulate MICAL-L2 expression. Cell proliferation was measured by EdU staining and CCK-8 assays. MICAL-L2 and phosphorylated/total c-Myc expression were examined by Western blotting analysis. Interaction between MICAL-L2 and c-Myc was assessed by immunofluorescence staining, Western blotting and co-immunoprecipitation assays. Western blotting, polyubiquitylation detection and protein stability assays were used to assess whether MICAL-L2 exerts its oncogenic effect via c-Myc. Results: We found that MICAL-L2 was highly expressed in human NSCLC. While overexpressing MICAL-L2 increased NSCLC cell proliferation, MICAL-L2 depletion decreased the proliferation of NSCLC cells, an effect that was linked to cell cycle arrest. MICAL-L2 physically interacted with the c-Myc protein and functioned to maintain nuclear c-Myc levels and prolonged its half-life. Knockdown of MICAL-L2 expression led to decreased c-Myc protein stability through accelerating polyubiquitylation of c-Myc and gave rise to c-Myc degradation. We further found that MICAL-L2 deubiquitinated c-Myc and blocked its degradation, presumably by inhibiting c-Myc phosphorylation at threonine residue 58. Conclusions: These results indicate that MICAL-L2 is a key regulator of c-Myc deubiquitination and stability in the nucleus, and this activity may be involved in promoting NSCLC cell proliferation.Funding Information
- National Natural Science Foundation of China (81602561, 82073226, 81773107)
This publication has 36 references indexed in Scilit:
- MICAL1 facilitates breast cancer cell proliferation via ROS‐sensitive ERK/cyclin D pathwayJournal of Cellular and Molecular Medicine, 2018
- Overexpression of MICAL2, a novel tumor-promoting factor, accelerates tumor progression through regulating cell proliferation and EMTJournal of Cancer, 2018
- Emerging roles of MICAL family proteins – from actin oxidation to membrane trafficking during cytokinesisJournal of Cell Science, 2017
- MICAL1 controls cell invasive phenotype via regulating oxidative stress in breast cancer cellsBMC Cancer, 2016
- MICAL-Family Proteins: Complex Regulators of the Actin CytoskeletonAntioxidants and Redox Signaling, 2014
- MYC DegradationCold Spring Harbor Perspectives in Medicine, 2014
- MYC on the Path to CancerCell, 2012
- Differential regulation of actin microfilaments by human MICAL proteinsJournal of Cell Science, 2012
- Proteomic profiling of Myc-associated proteinsCell Cycle, 2010
- c-Myc Target Genes Involved in Cell Growth, Apoptosis, and MetabolismMolecular and Cellular Biology, 1999